<DOC>
	<DOCNO>NCT00590226</DOCNO>
	<brief_summary>High blood glucose level hospitalize patient diabetes associate increased risk medical complication . Improved glucose control insulin injection may improve clinical outcome prevent hospital complication . It know ; however , best insulin regimen hospitalize patient . Recently , use basal/bolus insulin therapy detemir ( Levemir® ) rapid-acting insulin ( lispro , aspart , glulisine ) show facilitate outpatient glycemic control low rate hypoglycemic ( low blood sugar ) event patient diabetes . In study , determine efficacy safety combination detemir aspart insulin inpatient management subject diabetes . We hypothesize patient type 2 diabetes admit general medicine ward , treatment insulin detemir daily plus insulin aspart meal allow good glycemic control lower rate hypoglycemic event treatment twice day NPH plus regular insulin meal . Detemir long-acting insulin give subcutaneously ( skin ) daily . Aspart rapid-acting insulin give subcutaneously several time day frequently meal . Detemir aspart insulin approve use treatment patient diabetes FDA . This investigator-initiated research conduct Grady Memorial Hospital , Atlanta Rush University Medical Center , Chicago , IL . Dr. Umpierrez design study serve principal investigator . A total 65 patient recruit Grady 65 patient Rush University Medical Center , Chicago , IL .</brief_summary>
	<brief_title>Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>1 . Males female age 18 70 year admit general medical service . 2 . A known history type 2 diabetes mellitus &gt; 3 month , receive combination oral antidiabetic agent ( sulfonylurea , metformin , thiazolidinediones ) and/or insulin therapy . 3 . Subjects must admission blood glucose &gt; 140 mg &lt; 400 mg/dL evidence ketoacidosis ( serum bicarbonate &lt; 18 mEq/L , venous arterial pH &lt; 7.30 , positive serum urinary ketone ) . 1 . Subjects increase blood glucose concentration , without know history diabetes . 2 . Subjects history acute hyperglycemic crisis diabetic ketoacidosis hyperosmolar hyperglycemic state , ketonuria [ 63 ] . 3 . Patients acute critical surgical illness and/or expect require admission critical care unit ( ICU , CCU ) , undergo surgery hospitalization course . 4 . Patients clinically relevant hepatic disease ( ALT 2.5x &gt; upper limit normal ) , impaired renal function , show serum creatinine ≥2.0 mg/dL male , ≥ 1.8 mg/dL female . 5 . History drug alcohol abuse within last 2 year . 6 . Mental condition render subject unable understand nature , scope , possible consequence study . 7 . Patients recognize suspected endocrine disorder associate increased insulin resistance , hypercortisolism , acromegaly , hyperthyroidism . 8 . Female subject pregnant breast feeding time enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>inpatient hyperglycemia</keyword>
	<keyword>SQ insulin</keyword>
	<keyword>Hospitalized patient type 2 diabetes</keyword>
</DOC>